Compare Ascendis Pharma A/S (ASND) vs Etsy Inc (ETSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Etsy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Etsy Inc trades at $80.74 (market cap $7.69B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Etsy Inc's market cap. Which is the better fit depends on your goals.
| ASND | ETSY | |
|---|---|---|
Market Cap | $17.74B | $7.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $81.05 |
52-Week Low | $163.32 | $44.05 |
Enterprise Value | $18.11B | $9.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ETSY trades at $81.05, up 4.28% recently, with a bullish technical outlook supported by positive moving averages and recent earnings beats. The company shows strong gross margins of 71.55% and positive cash flow trends, though net income declined to $162.98M in 2025. Analyst sentiment is mixed with 49% buy ratings but a consensus price target of $70.79 below current levels, highlighting valuation concerns amid competitive pressures.
Outlook remains cautious due to high P/E of 31.05 and negative shareholder equity, offset by operational improvements and AI-driven seller tools. Key risks include active buyer declines and heavy debt load, but sustained GMS growth and cost management could support recovery if execution strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
